Clinical and Molecular Characteristics of GNAS Inactivation Disorders Observed in 18 Korean Patients

Abstract

Background The GNAS gene on chromosome 20q13.3 is a complex, imprinted locus regulated in a tissue-specific manner. GNAS inactivation disorders are a heterogeneous group of rare disorders caused by mutations and methylation defects. These are divided into pseudohypoparathyroidism (PHP) types 1A and 1B, pseudo-pseudohypoparathyroidism (PPHP), and progressive osseous heteroplasia (POH), depending on the presence or absence of hormone resistance, Albright’s hereditary osteodystrophy (AHO), and ectopic ossification.

Methods This study analyzed the clinical characteristics and molecular genetic backgrounds of 18 Korean patients from 16 families with a genetically confirmed GNAS defect. Auxological parameters, AHO phenotypes, types of hormonal resistance, family history, and molecular genetic disturbances were reviewed retrospectively.

Results Nine (90%) patients with PHP1A showed resistance to parathyroid hormone (PTH) and all patients showed elevated thyroid-stimulating hormone (TSH) levels at diagnosis. Eight (80%) patients were managed with levothyroxine supplementation. Three of six patients with PHP1B had elevated TSH levels, but none of whom needed levothyroxine medication. AHO features were absent in PHP1B. Patients with PPHP and POH did not show any hormone resistance, and both of them were born as small for gestational age. Among the 11 families with PHP1A, PPHP, and POH, eight different (three novel) mutations in the GNAS gene were identified. Among the six patients with PHP1B, two were sporadic cases and four showed isolated loss of methylation at GNAS A/B:TSS-DMR.

Conclusions Clinical and molecular characteristics of Korean patients with GNAS inactivation disorders were described in this study. Also, we reaffirmed heterogeneity of PHP, contributing to further accumulation and expansion of current knowledge of this complex disease.

Key words

pseudohypoparathyroidism - pseudo-pseudohypoparathyroidism - progressive osseous heteroplasia - Albright’s hereditary osteodystrophy

Publication History

Received: 21 January 2019
Received: 03 May 2019

Accepted: 01 July 2019

Article published online:
23 September 2019

• References

• 1 Mantovani G, Bastepe M, Monk D. et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: First international Consensus Statement. Nat Rev Endocrinol 2018; 14: 476-500
• 2 Nakamura Y, Matsumoto T, Tamakoshi A. et al. Prevalence of idiopathic hypoparathyroidism and pseudohypoparathyroidism in Japan. J Epidemiol 2000; 10: 29-33
• 3 Underbjerg L, Sikjaer T, Mosekilde L. et al. Pseudohypoparathyroidism - epidemiology, mortality and risk of complications. Clin Endocrinol (Oxf) 2016; 84: 904-911
• 4 Elli FM, Linglart A, Garin I. et al. The prevalence of GNAS deficiency-related diseases in a large cohort of patients characterized by the EuroPHP Network. J Clin Endocrinol Metab 2016; 101: 3657-3668
• 5 Bastepe M, Pincus JE, Sugimoto T. et al. Positional dissociation between the genetic mutation responsible for pseudohypoparathyroidism type Ib and the associated methylation defect at exon A/B: Evidence for a long-range regulatory element within the imprinted GNAS1 locus. Hum Mol Genet 2001; 10: 1231-1241
• 6 Fernandez-Rebollo E, Lecumberri B, Gaztambide S. et al. Endocrine profile and phenotype-(epi)genotype correlation in Spanish patients with pseudohypoparathyroidism. J Clin Endocrinol Metab 2013; 98: E996-E1006
• 7 Mantovani G, de Sanctis L, Barbieri AM. et al. Pseudohypoparathyroidism and GNAS epigenetic defects: Clinical evaluation of Albright hereditary osteodystrophy and molecular analysis in 40 patients. J Clin Endocrinol Metab 2010; 95: 651-658
• 8 de Sanctis L, Giachero F, Mantovani G. et al. Genetic and epigenetic alterations in the GNAS locus and clinical consequences in Pseudohypoparathyroidism: Italian common healthcare pathways adoption. Ital J Pediatr 2016; 42: 101
• 9 Bastepe M, Frohlich LF, Hendy GN. et al. Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest 2003; 112: 1255-1263
• 10 Linglart A, Gensure RC, Olney RC. et al. A novel STX16 deletion in autosomal dominant pseudohypoparathyroidism type Ib redefines the boundaries of a cis-acting imprinting control element of GNAS. Am J Hum Genet 2005; 76: 804-814
• 11 Richard N, Abeguile G, Coudray N. et al. A new deletion ablating NESP55 causes loss of maternal imprint of A/B GNAS and autosomal dominant pseudohypoparathyroidism type Ib. J Clin Endocrinol Metab 2012; 97: E863-E867
• 12 Kim JH, Yun S, Hwang S-s. et al. The 2017 Korean National Growth Charts for children and adolescents: Development, improvement, and prospects. Korean J Pediatr 2018; 61: 135-149
• 13 Yuno A, Usui T, Yambe Y. et al. Genetic and epigenetic states of the GNAS complex in pseudohypoparathyroidism type Ib using methylation-specific multiplex ligation-dependent probe amplification assay. Eur J Endocrinol 2013; 168: 169-175
• 14 Lemos MC, Thakker RV. GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders. Hum Mutat 2015; 36: 11-19
• 15 Monk D, Morales J, den Dunnen JT. et al. Recommendations for a nomenclature system for reporting methylation aberrations in imprinted domains. Epigenetics 2018; 13: 117-121
• 16 Elli FM, de Sanctis L, Ceoloni B. et al. Pseudohypoparathyroidism type Ia and pseudo-pseudohypoparathyroidism: The growing spectrum of GNAS inactivating mutations. Hum Mutat 2013; 34: 411-416
• 17 Mantovani G, Romoli R, Weber G. et al. Mutational analysis of GNAS1 in patients with pseudohypoparathyroidism: Identification of two novel mutations. J Clin Endocrinol Metab 2000; 85: 4243-4248
• 18 Sano S, Nakamura A, Matsubara K. et al. (Epi)genotype-phenotype analysis in 69 Japanese patients with pseudohypoparathyroidism type I. J Endocr Soc 2018; 2: 9-23
• 19 Turan S, Ignatius J, Moilanen JS. et al. De novo STX16 deletions: An infrequent cause of pseudohypoparathyroidism type Ib that should be excluded in sporadic cases. J Clin Endocrinol Metab 2012; 97: E2314-E2319
• 20 Grigelioniene G, Nevalainen PI, Reyes M. et al. A Large inversion involving GNAS Exon A/B and all exons encoding gsalpha is associated with autosomal dominant pseudohypoparathyroidism type Ib (PHP1B). J Bone Miner Res 2017; 32: 776-783
• 21 Gelfand IM, Eugster EA, DiMeglio LA. Presentation and clinical progression of pseudohypoparathyroidism with multi-hormone resistance and Albright hereditary osteodystrophy: A case series. J Pediatr 2006; 149: 877-880
• 22 Mantovani G, Ferrante E, Giavoli C. et al. Recombinant human GH replacement therapy in children with pseudohypoparathyroidism type Ia: First study on the effect on growth. J Clin Endocrinol Metab 2010; 95: 5011-5017
• 23 Richard N, Molin A, Coudray N. et al. Paternal GNAS mutations lead to severe intrauterine growth retardation (IUGR) and provide evidence for a role of XLalphas in fetal development. J Clin Endocrinol Metab 2013; 98: E1549-E1556
• 24 Xie T, Plagge A, Gavrilova O. et al. The alternative stimulatory G protein alpha-subunit XLalphas is a critical regulator of energy and glucose metabolism and sympathetic nerve activity in adult mice. J Biol Chem 2006; 281: 18989-18999
• 25 Hanna P, Grybek V, Perez de Nanclares G. et al. Genetic and epigenetic defects at the GNAS locus lead to distinct patterns of skeletal growth but similar early-onset obesity. J Bone Miner Res 2018; 33: 1480-1488
• 26 Cho SY, Yoon YA, Ki CS. et al. Clinical characterization and molecular classification of 12 Korean patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism. Exp Clin Endocrinol Diabetes 2013; 121: 539-545